BRITISH cannabis firm GW Pharmaceuticals is close to securing European approval for its Epidiolex drug after seeing its success in the U.S. lead to record sales. NASDAQ-listed GW Pharmaceuticals announced its second quarter results with revenue topping $72 million, far above the $3.3 million in the same period, last year – and surpassing analysts’ expectations … Continue reading Epidiolex Launch in U.S. Prompts GW Pharmaceuticals Sales Surge